Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.48) by 14.58 percent. This is a 7.84 percent decrease over losses of $(0.51) per share from the same period last year.
GSK’s Jemperli Plus Chemo Combo Scores FDA Approval As First New Frontline Treatment For Certain Type Of Endometrial Cancer
The FDA approved GSK plc's (NYSE: GSK) Jemperli (dostarlimab) in combination with carboplatin and paclitaxel, followed by Jemperli as a single agent for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined b
